| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | 0.31 | 5e-15 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | 0.29 | 4e-07 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 4e-07 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | -0.2 | 2e-06 |
| mRNA | RO4929097 | CTRPv2 | pan-cancer | AAC | 0.26 | 2e-06 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | 0.14 | 1e-05 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.21 | 2e-05 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.17 | 4e-05 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.16 | 5e-05 |
| mRNA | QW-BI-011 | CTRPv2 | pan-cancer | AAC | 0.27 | 9e-05 |